Skip to main content
Article thumbnail
Location of Repository

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

By Mozhgan Dorkhan, Magnus Dencker, Martin Stagmo and Leif Groop
Topics: Original Investigation
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2664795
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). A: Treatment with a thiazolidinedione induced significant, reversible mitral regurgitation. Cardiovasc Diabetol
    2. (2008). Braunwald E: State of the art: using natriuretic peptide levels in clinical practice.
    3. (2008). DH: Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med
    4. (2007). Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care
    5. (2002). M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care
    6. (2005). Parving HH: Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia
    7. (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    8. (2005). Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.
    9. (2005). Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia
    10. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet
    11. (2006). Tajik AJ, Tsang TS: Left atrial size: physiologic determinants and clinical applications.
    12. (2001). Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.